PureTech Health
3
FDA Approvals
80%
Clinical Trial Success Rate
$4.6B
Funds Raised for Founded Entities Since 2018
The Cavendish View
PureTech offers a differentiated biotechnology investment model centred on creating, clinically de-risking and externalising innovative therapeutic assets while retaining long-term equity, royalty and milestone economics, providing an attractive risk-reward profile relative to traditional single-asset biotechnology companies. This is an opportunity to engage with management on the evolution of the Founded Entity strategy, the recent US$180m Celea financing, future value realisation opportunities and the company's increasing focus on disciplined capital allocation and long-term shareholder returns.
ADAM MCCARTER
Research Associate Director
Giving Life to Science
PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.
For more information, visit www.puretechhealth.com or connect with us on LinkedIn and X (formerly Twitter) @puretechh.
Attending from PureTech Health
Robert Lyne
Chief Executive Officer
Company descriptions are drawn from information published by each company and have not been independently verified by Cavendish. They are for information only, are not investment research, advice or a recommendation, and do not constitute an offer or invitation to buy or sell any security. Information is correct as at 10th September 2026 and will not be updated. Investors should refer to each company's own published announcements and accounts. Cavendish acts as adviser or broker to certain of the companies featured.